Skin cancer -an overview for dentists

British Dental Journal

Volumn 216, Issue 10, 2014, Pages 575-581

  Steel, B J ^a,b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DENTIST; GREAT BRITAIN; HEAD; HUMAN; MELANOMA; NECK; RISK FACTOR; SKIN NEOPLASMS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DENTISTS; GREAT BRITAIN; HEAD; HUMANS; MELANOMA; NECK; RISK FACTORS; SKIN NEOPLASMS;

EID: 84901457035     PISSN: 00070610     EISSN: 17417503     Source Type: Journal    
DOI: 10.1038/sj.bdj.2014.399     Document Type: Article

References (38)

1. Cancer Research UK. UK Cancer incidence 2010. Cancer Research UK, 2012.
2. Faculty of General Dental Practitioners at the Royal College of Surgeons of England. Clinical examination and record keeping: good practice guidelines. London: FGDP UK, 2009.
3. The Information Centre for Health and Social Care. NHS dental statistics for England. 2012-2013 First quarterly report. HSCIC, 2012.
4. South West Public Health Authority Skin Cancer Hub. Online information available at www.swpho. nhs. uk/skincancerhub/(accessed March 2014).
5. Brewster D H, Bhatti L A, Inglis J H, Nairn E R, Doherty V R. Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003. Br J Dermatol 2007; 156: 1295-1300.
6. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 2007; 121: 2105-2108.
7. Marcil I, Stern R S. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer. Arch Dermatol 2000; 136: 1524-1530.
8. National Institute for Health and Care Excellence. Improving outcomes for people with skin tumours including melanoma (update): the management of low-risk basal cell carcinomas in the community. London: NICE, 2010.
9. Kim M, Park H J, Baek S C, Byun D G, Houh D. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci 2002; 29: 1-9.
10. Neville B W, Damm D D, Allen C M, Bouquot J E. Oral and maxillofacial pathology. 2nd ed. Philadelphia: Saunders, 2002.
11. Rahbari H, Mehregan A H. Basal cell naevus epithelioma [cancer in children and teenagers]. Cancer 1982; 49: 350-353.
12. Breuninger H, Dietz K. Prediction of subclinical tumour infiltration in basal cell carcinoma. J Dermatol Surg Oncol 1991; 17: 574-578.
13. Holme S A, Malinovszky K, Roberts D L. Changing trends in non-melanoma skin cancer in South Wales. Br J Dermatol 2000; 143: 1224-1229.
14. Telfer N R, Colver G B, Morton C A. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
15. Amin S H, Motamedi K K, Ochsner M C, Song T E, Hybarger C P. Mechanisms and efficacy of vismodegib in the treatment of basal cell carcinoma. Discov Med 2013; 16: 229-232.
16. Karagas M R, Stannard V A, Mott L A, Slattery M J, Spencer S K, Weinstock M A. Use of tanning devices and risk of basal cell and squamous cell cancers. J Natl Cancer Inst 2002; 94: 224-226.
17. Schmitt J, Seidler A, Diepgen T L, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: A systematic review and meta-analysis. Br J Dermatol 2011; 164: 291-307.
18. Rosso S, Zanetti R, Martinez C et al. The multicentre south European study 'Helios'. II: different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1447-1454.
19. Birch-Johansen F, Norrild B, Olesen A B, Jensen A, Kjaer S K. HPV infection might play a role in the development of nonmelanoma skin cancer in immunocompetent individuals. Ugeskr Laeger 2012; 174: 413-417.
20. Song F, Qureshi A A, Gao X, Li T, Han J. Smoking and risk of skin cancer: A prospective analysis and a meta-analysis. Int J Epidemiol 2012; 41: 1694-1705.
21. Nouri K. Skin cancer. McGraw Medical. 2008.
22. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales skin cancer study. Br J Cancer 1996; 74: 1302-1307.
23. Halpern A C, Hanson L J. Awareness of, knowledge of, and attitudes to non-melanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol 2004; 43: 638-642.
24. Motley R J, Preston P W, Lawrence C M. Multi-professional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. London: British Association of Dermatologists, 2009.
25. Rowe D E, Carroll R J, Day C L Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-990.
26. de Berker D, McGregor J M, Hughes B R. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222-230.
27. Misago N, Inoue T, Koba S, Narisawa Y. Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture: classification and identification. J Dermatol 2013; 40: 443-452.
28. Cancer Research UK. Skin cancer incidence statistics. Cancer Research UK, 2011. Online statistics available at http://www.cancerresearchuk. org/cancer-info/cancerstats/types/skin/incidence/uk-skin-cancer-incidence- statistics (accessed March 2014).
29. Cho E, Rosner B A, Colditz G A. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev 2005; 14: 1241.
30. Kubica A W, Brewer J D. Melanoma in immunosuppressed patients. Mayo Clin Prog 2012; 87: 991-1003.
31. Gandini S, Sera F, Cattaruzza M S et al. Meta-analysis of risk factors for cutaneous melanoma. III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-2059.
32. International agency for research on cancer working group on artificial ultraviolet light and skin cancer. The association of use of sunbeds with cutaneous melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120: 1116-1122.
33. Weinstock M A, Sober A J. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116: 303-310.
34. Marsden J R, Newton-Bishop J A, Burrows L et al. Revised UK guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163: 238-256.
35. Morton D L, Thompson J F, Cochran A J. Sentinel node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317.
36. Flaherty K T, Hodi F S, Bastian B C. Mutation-driven drug development in melanoma. Curr Opin Oncol 2010; 22: 178-183.
37. The British Association of Dermatology. Skin cancer: patient information leaflet. Online leaflet available at http://www.bad. org. uk/site/875/Default. aspx (accessed March 2014).
38. National Institute for Health and Care Excellence. Improving outcomes for people with skin tumours including melanoma. London: NICE, 2006. Online guidance available at ttp://www.nice. org. uk/nicemedia/live/10901/28906/28906. pdf (accessed March 2014).